Neonatal Respiratory Distress Syndrome And Modern Surfactant Care

Neonatal respiratory distress syndrome (RDS) remains one of the most important causes of breathing difficulty in premature infants. Immature lungs produce too little endogenous surfactant, allowing alveoli to collapse at the end of expiration. The resulting low lung compliance, oxygen deficiency, and increased work of breathing can progress rapidly after birth.

Surfactant replacement has changed substantially since the era of routine prophylactic intubation. Current care places greater emphasis on antenatal corticosteroids, early noninvasive respiratory support, careful oxygen targeting, and administration through techniques that preserve spontaneous breathing. The objective is to correct surfactant deficiency while limiting ventilator-induced lung injury.

Research presented through international perinatal and neonatal societies has helped shape this approach. The archived congress site reflects the scientific setting in which clinicians and researchers shared work on neonatal respiratory care, perinatal medicine, and outcomes across Asian and Oceania health systems.

Why Respiratory Distress Still Matters

RDS is most common in infants born at lower gestational ages, although late-preterm and term newborns can develop respiratory failure for other reasons. A deficient pulmonary surfactant layer increases surface tension inside the alveoli. This promotes atelectasis, reduces functional residual capacity, and creates a mismatch between ventilation and perfusion.

Clinical signs may include tachypnea, grunting, nasal flaring, intercostal retractions, and increasing oxygen requirements. Chest radiography can show a diffuse reticulogranular pattern with air bronchograms, though lung ultrasound is increasingly used to support early diagnosis and guide treatment. Blood gas results, oxygen trends, gestational age, and the infant’s response to continuous positive airway pressure (CPAP) are considered together.

The consequences extend beyond the first hours of life. Severe RDS may require mechanical ventilation and can contribute to pneumothorax, bronchopulmonary dysplasia, intraventricular hemorrhage, and prolonged hospitalization. Prompt stabilization therefore involves more than administering a drug; it requires a coordinated respiratory strategy that protects the developing lung.

How Surfactant Treatment Has Evolved

Exogenous surfactant preparations contain phospholipids and, depending on the product, surfactant-associated proteins that improve spreading across the alveolar surface. Animal-derived preparations such as poractant alfa, beractant, and bovine lipid extract surfactant are widely used in many regions. Their composition, concentration, approved indications, and dosing schedules differ, so local protocols and product information remain important.

A major change is the move from routine early intubation toward selective rescue therapy. Infants who are breathing spontaneously on CPAP may receive surfactant through a thin catheter, commonly called less invasive surfactant administration (LISA) or minimally invasive surfactant therapy (MIST). This approach avoids prolonged endotracheal ventilation in appropriately selected newborns and may reduce exposure to mechanical ventilation.

The timing of treatment has also become more responsive to clinical need. Early surfactant is generally favored when an extremely preterm infant has signs of RDS and requires escalating oxygen or pressure support despite effective CPAP. Stable infants who maintain acceptable oxygenation on noninvasive support may be monitored rather than intubated solely to provide prophylactic surfactant.

Selecting The Product And Delivery Method

Poractant alfa is frequently used at an initial dose of 200 mg/kg in protocols based on evidence that a higher first dose can improve early respiratory outcomes compared with lower dosing. Other preparations use different volumes and dosing conventions. Clinicians must calculate the dose from the infant’s current weight, confirm the concentration, warm the product according to instructions, and prepare for transient changes in oxygenation and compliance.

LISA or MIST is often considered when the infant has spontaneous respiratory effort, a suitable airway, and sufficient cardiorespiratory stability. A laryngoscope is used to place a thin catheter through the vocal cords, after which surfactant is administered while CPAP continues. Gentle handling, skilled airway management, and a team familiar with the procedure can improve success.

The INSURE technique—intubation, surfactant administration, and rapid extubation to CPAP—remains useful when thin-catheter treatment is unavailable, unsuccessful, or unsuitable. It may be chosen for an infant with worsening apnea, severe respiratory acidosis, or a need for controlled airway support. The best method depends on gestational age, respiratory drive, local expertise, and the infant’s response rather than on a single universal pathway.

Timing Doses And Repeat Treatment

Treatment thresholds vary by guideline and unit, but a rising fraction of inspired oxygen requirement on CPAP is often used as a practical signal. A commonly applied threshold is an oxygen need around 0.30, although gestational age, pressure level, work of breathing, blood gas values, and overall trajectory should influence the decision. Delaying therapy until severe respiratory failure can increase the need for invasive ventilation.

Surfactant is delivered through an endotracheal tube, thin catheter, or another approved route. Transient bradycardia, desaturation, reflux of medication, and uneven distribution can occur. Respiratory support should be adjusted promptly as lung compliance improves, because pressure and oxygen needs may fall within minutes.

A second dose can be considered when the infant has persistent or recurrent RDS with ongoing oxygen and ventilatory requirements after the first treatment. Before repeating surfactant, the team should check for pneumothorax, pulmonary hemorrhage, pneumonia, patent ductus arteriosus, atelectasis, poor CPAP interface, and incorrect endotracheal tube position. Repeated dosing should address a clear clinical problem rather than follow an automatic schedule.

Protecting The Lung During Recovery

Surfactant works best when paired with gentle respiratory support. CPAP helps maintain alveolar recruitment, while synchronized noninvasive ventilation may assist infants with apnea or inadequate respiratory effort. If intubation is necessary, volume-targeted ventilation can reduce excessive tidal volumes as compliance improves. Frequent reassessment is essential because a setting that was appropriate before surfactant may become excessive afterward.

Oxygen should be titrated to the target range used by the neonatal unit. Both hypoxemia and hyperoxemia can harm premature infants, so pulse oximetry must be interpreted alongside perfusion, blood gases, and clinical condition. Heated humidification, thermoregulation, and appropriate interface sizing also affect respiratory stability.

Lung ultrasound is gaining value as a bedside tool for identifying interstitial patterns, consolidations, and changes after surfactant treatment. It can support decisions about treatment timing while reducing reliance on repeated radiographs. It does not replace clinical judgment, especially when infection, transient tachypnea, pulmonary hypertension, or congenital lung disease remains possible.

Emerging Directions In Surfactant Research

Synthetic surfactants containing functional peptides are an active research area. These products aim to reproduce the spreading and surface-tension-lowering activity associated with natural surfactant proteins while offering more consistent manufacturing and avoiding animal-derived components. Their availability and regulatory status differ widely, so they should not be treated as interchangeable with established preparations.

Aerosolized or nebulized surfactant could eventually deliver therapy without laryngoscopy or catheter placement. Early studies have explored vibrating-membrane nebulizers and other devices, but delivery efficiency, deposition in the distal lung, and clinical outcome evidence remain variable. At present, noninvasive aerosol delivery is best viewed as an evolving research field rather than a universal replacement for established administration methods.

Future studies are also examining individualized treatment thresholds, artificial intelligence for lung imaging, improved prediction of bronchopulmonary dysplasia, and strategies that combine surfactant with optimized noninvasive ventilation. Meaningful progress will require outcomes that include survival without severe respiratory morbidity, neurodevelopment, family burden, and resource use—not simply short-term oxygen reduction.

Practical Bedside Recommendations

A consistent team approach helps translate updated evidence into safe neonatal care. Protocols should define how infants are assessed in the delivery room, when CPAP is started, which oxygen thresholds prompt surfactant, how doses are verified, and when escalation to invasive ventilation is appropriate.

Training is particularly important for LISA, MIST, and rapid extubation pathways. Simulation can improve airway coordination, medication preparation, and recognition of complications. Each infant still requires individualized care, especially when the clinical picture does not fit uncomplicated RDS.

• Give antenatal corticosteroids when preterm birth is likely and the clinical situation allows.
• Start effective noninvasive respiratory support early for spontaneously breathing preterm infants.
• Consider early surfactant when oxygen needs and work of breathing rise despite optimized CPAP.
• Use a product-specific dose, route, and repeat-treatment policy rather than relying on memory.
• Reassess the diagnosis and ventilator settings immediately after surfactant improves lung compliance.

Surfactant replacement is most effective when it forms part of a complete respiratory bundle: prevention before birth, stabilization after delivery, timely treatment, protective ventilation, and careful follow-up. Neonatal teams can use current evidence to reduce unnecessary intubation while avoiding delays that expose fragile infants to worsening respiratory failure. Applying these principles at the bedside supports safer transitions from distress to stable breathing and helps advance the long-term goals of perinatal medicine.